Novo Nordisk and OpenAI announce partnership to use AI in drug development and operations
The Facts
- Novo Nordisk and OpenAI announced a strategic partnership on April 14 to use AI across Novo Nordisk's business.
- Novo Nordisk said the partnership will apply OpenAI's technology to drug discovery as well as manufacturing and commercial or corporate operations.
- The companies said AI will be used to analyze complex datasets and identify promising drug candidates.
- Novo Nordisk said the collaboration is intended to reduce the time needed to move from research to delivering treatments to patients.
- Novo Nordisk is the maker of the diabetes and obesity drugs Ozempic and Wegovy.
- Reuters and other outlets said drugmakers are increasingly using AI to speed or streamline parts of drug development and related processes.
- Novo Nordisk did not disclose the financial terms of the partnership.
Context
What will the partnership be used for?
Novo Nordisk said it will use OpenAI's technology across drug discovery and broader operations, including manufacturing, supply chain, distribution and commercial functions, to help employees analyze data and work more efficiently WSJ,Yahoo! Finance,elEconomista.es.
What problem is Novo Nordisk trying to solve with AI?
According to the company, the goal is to find promising drug candidates faster and shorten the path from research to patient access by using AI to process large, complex datasets and test hypotheses more quickly CNBC,Euronews English,Morningstar.
Why is this partnership drawing attention now?
The deal fits into a broader push by pharmaceutical companies to use AI in development and operations, and it comes as Novo Nordisk faces intense competition in the obesity-drug market from Eli Lilly Reuters,Bloomberg Business,CNA.
View all 73 sources
Wire services (5)
Independent coverage (50)
About these frames
See this differently than someone you know would? Two ways to keep it going.
The dial works on any URL — paste an article you read elsewhere this week.